Tobias Bexte
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tobias Bexte has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Evelyn Ullrich
Department of Pediatrics, Experimental Immunology and Cell Therapy, Goethe University Frankfurt, Frankfurt am Main, Germany
5 shared publications - Avani Sapre
Goethe University
2 shared publications - Kuan-Yu Lai
Goethe University
2 shared publications - Lea Rebecca Knapp
Goethe University
2 shared publications - Meike Vogler
Institute for Experimental Pediatric Hematology and Oncology, Goethe University Frankfurt, Frankfurt, Germany
2 shared publications - Mubin Tarannum
Dana Farber Cancer Institute
2 shared publications
Latest Publications
- 18 November 2026
- Published by SAGE Publications in Human Gene Therapy
Killers by Design: How Innovative Gene-Engineering Fine-Tunes NK Cells as Next Generation Immunotherapies
Natural killer (NK) cells have emerged as promising candidates for adoptive immunotherapies. Their natural cytotoxic capabilities and low incidence of side-effects such as cytokine release syndrome and immune effector cell-associated neurotoxicity, render NK cells a favorable alternative to T cells. Incorporation of a chimeric antigen receptor (CAR) has been shown to greatly enhance NK cell’s antitumor capacity. Nevertheless, CAR-NK cell therapies still face several challenges, such as low in vivo persistence, low tumor homing of the transfused cells and the effects of the immunosuppressive tumor microenvironment (TME). Genetic modifications of key cellular mediators show great potential to overcome these hurdles. While well-established viral engineering strategies are currently the most commonly used techniques, biosafety concerns, high costs, and labour-intensive protocols have encouraged innovation toward nonviral strategies. In this review, we describe recently established viral and nonviral technologies used for NK cell engineering, focusing on their respective advantages and disadvantages. In addition, we highlight the most important functional refinements and mechanistic characterizations of NK cells and genetically optimized NK cells in the context of the TME and how these advances can be progressed toward therapeutic translation.
- 18 November 2026
- Published by SAGE Publications in Human Gene Therapy
Killers by Design: How Innovative Gene-Engineering Fine-Tunes NK Cells as Next Generation Immunotherapies
Natural killer (NK) cells have emerged as promising candidates for adoptive immunotherapies. Their natural cytotoxic capabilities and low incidence of side-effects such as cytokine release syndrome and immune effector cell-associated neurotoxicity, render NK cells a favorable alternative to T cells. Incorporation of a chimeric antigen receptor (CAR) has been shown to greatly enhance NK cell’s antitumor capacity. Nevertheless, CAR-NK cell therapies still face several challenges, such as low in vivo persistence, low tumor homing of the transfused cells and the effects of the immunosuppressive tumor microenvironment (TME). Genetic modifications of key cellular mediators show great potential to overcome these hurdles. While well-established viral engineering strategies are currently the most commonly used techniques, biosafety concerns, high costs, and labour-intensive protocols have encouraged innovation toward nonviral strategies. In this review, we describe recently established viral and nonviral technologies used for NK cell engineering, focusing on their respective advantages and disadvantages. In addition, we highlight the most important functional refinements and mechanistic characterizations of NK cells and genetically optimized NK cells in the context of the TME and how these advances can be progressed toward therapeutic translation.
- 5 November 2026
- Published by Springer Nature
- p. 1-34
Genetic Engineering of Natural Killer Cells: Unleashing Their Killer Instincts
- 5 November 2026
- Published by Springer Nature
- p. 1-34
Genetic Engineering of Natural Killer Cells: Unleashing Their Killer Instincts
- 27 September 2026
- Published by Springer Nature
- p. 1-35
Genetic Engineering of Natural Killer Cells: Unleashing Their Killer Instincts
- 27 September 2026
- Published by Springer Nature
- p. 1-35
Genetic Engineering of Natural Killer Cells: Unleashing Their Killer Instincts
- Open Access
- 10 February 2026
- Published by Elsevier in Molecular Therapy Oncology
- Vol. 34 (1) , 201135
Come together: The BE-TILs—Efficient multiplex base editing of tumor-infiltrating lymphocytes
- 10 February 2026
- Published by Elsevier in Molecular Therapy Oncology
- Vol. 34 (1) , 201135
Open AccessCome together: The BE-TILs—Efficient multiplex base editing of tumor-infiltrating lymphocytes
- Open Access
- 5 December 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1711414
Engineering with care: safety assessment platforms for CRISPR-modified natural killer cells
CRISPR-based gene editing has become a transformative tool to enhance immune cell therapies. In particular, engineering natural killer (NK) cells with CRISPR/Cas systems has gained traction due to their ability to mediate strong anti-tumor responses in an MHC-unrestricted, non-alloreactive manner. Early trials show the feasibility and safety of allogeneic NK cells, paving the way as scalable “off-the-shelf” products. CRISPR/Cas9 edits genomes by inducing DNA double-strand breaks (DSBs), mainly repaired through non-homologous end joining (NHEJ) or homology-directed repair (HDR). While effective, CRISPR carries risks of off-target (OT) activity that may disrupt essential genes, cause chromosomal rearrangements, or trigger oncogenic changes - posing threats to product integrity and patient safety. These concerns intensify with multiplex editing, where multiple loci are modified to improve function, persistence, and immune evasion. Since unmodified NK cells are typically short-lived, many clinical-stage products are engineered to express IL-15 or related constructs, extending their half-life and amplifying risks associated with unintended changes. This underscores the urgent need for robust safety assessments. In this review, we summarize the current landscape of safety assessment platforms for evaluating gene edited NK cells. We highlight predictive in silico tools, biochemical in vitro assays, and emerging cell-based detection systems to identify and quantify CRISPR-induced OT events. Particular attention is given to their suitability, limitations, and practical use in primary NK cells and multiplex editing strategies. Our aim is to support the design of safe, effective editing workflows for NK cell therapies - ensuring rigor as the field advances rapidly toward clinical application.
- 5 December 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1711414
Open AccessEngineering with care: safety assessment platforms for CRISPR-modified natural killer cells
CRISPR-based gene editing has become a transformative tool to enhance immune cell therapies. In particular, engineering natural killer (NK) cells with CRISPR/Cas systems has gained traction due to their ability to mediate strong anti-tumor responses in an MHC-unrestricted, non-alloreactive manner. Early trials show the feasibility and safety of allogeneic NK cells, paving the way as scalable “off-the-shelf” products. CRISPR/Cas9 edits genomes by inducing DNA double-strand breaks (DSBs), mainly repaired through non-homologous end joining (NHEJ) or homology-directed repair (HDR). While effective, CRISPR carries risks of off-target (OT) activity that may disrupt essential genes, cause chromosomal rearrangements, or trigger oncogenic changes - posing threats to product integrity and patient safety. These concerns intensify with multiplex editing, where multiple loci are modified to improve function, persistence, and immune evasion. Since unmodified NK cells are typically short-lived, many clinical-stage products are engineered to express IL-15 or related constructs, extending their half-life and amplifying risks associated with unintended changes. This underscores the urgent need for robust safety assessments. In this review, we summarize the current landscape of safety assessment platforms for evaluating gene edited NK cells. We highlight predictive in silico tools, biochemical in vitro assays, and emerging cell-based detection systems to identify and quantify CRISPR-induced OT events. Particular attention is given to their suitability, limitations, and practical use in primary NK cells and multiplex editing strategies. Our aim is to support the design of safe, effective editing workflows for NK cell therapies - ensuring rigor as the field advances rapidly toward clinical application.
- Open Access
- 15 September 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (9) , e012841
Next-generation multiplex-edited CAR-NK cells: more edits, more power?
First clinical trials demonstrated the safety of adoptive cell transfer with allogeneic natural killer (NK) cell products from healthy donors, making them an attractive candidate for ‘off-the-shelf’ chimeric antigen receptor (CAR)-immune cell therapy. However, reduced persistence and inactivation of NK cells by immunosuppressive cues likely limit the performance of CAR-redirected NK cells. Wang and colleagues demonstrate that multiplex CRISPR base editing allows optimization of the intrinsic functionality of CAR-NK cells improving their therapeutic potential. In contrast to conventional CRISPR-Cas nucleases, base editing avoided most double-stranded DNA breaks while enabling highly efficient editing at up to six sites simultaneously. The study further demonstrates the feasibility of a non-viral approach to integrate CAR transgene and multiplex base editing of several immune checkpoints in NK cells using a single electroporation. CAR-NK cells harboring up to three base edits demonstrate improved potency over unedited counterparts in vitro. Xenograft mouse models confirmed increased potency, but also indicated signs of organ toxicity - a phenomenon that will require future studies prior to clinical translation. The study demonstrates that CRISPR base editing is a powerful tool to unleash the full cytotoxic potential of NK cells, but it also warrants the question: How many internal breaks can be removed without hurting CAR-NK cell therapy’s impeccable safety record?
- 15 September 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (9) , e012841
Open AccessNext-generation multiplex-edited CAR-NK cells: more edits, more power?
First clinical trials demonstrated the safety of adoptive cell transfer with allogeneic natural killer (NK) cell products from healthy donors, making them an attractive candidate for ‘off-the-shelf’ chimeric antigen receptor (CAR)-immune cell therapy. However, reduced persistence and inactivation of NK cells by immunosuppressive cues likely limit the performance of CAR-redirected NK cells. Wang and colleagues demonstrate that multiplex CRISPR base editing allows optimization of the intrinsic functionality of CAR-NK cells improving their therapeutic potential. In contrast to conventional CRISPR-Cas nucleases, base editing avoided most double-stranded DNA breaks while enabling highly efficient editing at up to six sites simultaneously. The study further demonstrates the feasibility of a non-viral approach to integrate CAR transgene and multiplex base editing of several immune checkpoints in NK cells using a single electroporation. CAR-NK cells harboring up to three base edits demonstrate improved potency over unedited counterparts in vitro. Xenograft mouse models confirmed increased potency, but also indicated signs of organ toxicity - a phenomenon that will require future studies prior to clinical translation. The study demonstrates that CRISPR base editing is a powerful tool to unleash the full cytotoxic potential of NK cells, but it also warrants the question: How many internal breaks can be removed without hurting CAR-NK cell therapy’s impeccable safety record?
- Open Access
- 7 July 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (7) , e011330
Precision targeting of rhabdomyosarcoma by combining primary CAR NK cells and radiotherapy
Background: Rhabdomyosarcoma (RMS) is the most common type of soft-tissue sarcoma in children, and it remains a challenging cancer with poor outcomes in high-risk and metastatic patients. This study reports the use of epidermal growth factor receptor (EGFR)-targeted chimeric antigen receptor (CAR) natural killer (NK) cells in combination with radiotherapy as a novel immunotherapeutic approach for RMS treatment. Methods: Primary human NK cells from healthy donors were engineered using lentiviral transduction to express a cetuximab-based EGFR-specific CAR. The ability of the engineered NK cells to lyse RMS cells was then assessed in vitro in RMS monolayers and spheroids, as well as against chemotherapy-resistant and primary patient-derived RMS cells. Migratory properties of NK cells were observed in a subcutaneous RMS xenograft model using in vivo imaging, and the efficacy of EGFR-CAR NK cells in combination with localized fractionated radiotherapy was analyzed. Results: Primary human EGFR-CAR NK cells demonstrated enhanced cytotoxicity against multiple RMS cell lines in both two-dimensional culture and three-dimensional spheroid models. Furthermore, EGFR-CAR NK cells were highly efficient against chemotherapy-resistant RMS cells and patient-derived samples. Importantly, EGFR-CAR NK cells also exhibited improved tumor homing compared with non-transduced NK cells in an in vivo RMS xenograft model. Notably, the combination of EGFR-CAR NK cell therapy with fractionated radiotherapy further enhanced NK cell infiltration into the tumor and reduced tumor growth. Conclusion: This study provides a proof-of-concept for EGFR-CAR NK cells as a promising immunotherapy for RMS, particularly when combined with radiotherapy to overcome barriers of solid tumors. This combinatorial approach may hold potential to improve outcomes for patients with RMS and other EGFR-expressing malignancies.
- 7 July 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (7) , e011330
Open AccessPrecision targeting of rhabdomyosarcoma by combining primary CAR NK cells and radiotherapy
Background: Rhabdomyosarcoma (RMS) is the most common type of soft-tissue sarcoma in children, and it remains a challenging cancer with poor outcomes in high-risk and metastatic patients. This study reports the use of epidermal growth factor receptor (EGFR)-targeted chimeric antigen receptor (CAR) natural killer (NK) cells in combination with radiotherapy as a novel immunotherapeutic approach for RMS treatment. Methods: Primary human NK cells from healthy donors were engineered using lentiviral transduction to express a cetuximab-based EGFR-specific CAR. The ability of the engineered NK cells to lyse RMS cells was then assessed in vitro in RMS monolayers and spheroids, as well as against chemotherapy-resistant and primary patient-derived RMS cells. Migratory properties of NK cells were observed in a subcutaneous RMS xenograft model using in vivo imaging, and the efficacy of EGFR-CAR NK cells in combination with localized fractionated radiotherapy was analyzed. Results: Primary human EGFR-CAR NK cells demonstrated enhanced cytotoxicity against multiple RMS cell lines in both two-dimensional culture and three-dimensional spheroid models. Furthermore, EGFR-CAR NK cells were highly efficient against chemotherapy-resistant RMS cells and patient-derived samples. Importantly, EGFR-CAR NK cells also exhibited improved tumor homing compared with non-transduced NK cells in an in vivo RMS xenograft model. Notably, the combination of EGFR-CAR NK cell therapy with fractionated radiotherapy further enhanced NK cell infiltration into the tumor and reduced tumor growth. Conclusion: This study provides a proof-of-concept for EGFR-CAR NK cells as a promising immunotherapy for RMS, particularly when combined with radiotherapy to overcome barriers of solid tumors. This combinatorial approach may hold potential to improve outcomes for patients with RMS and other EGFR-expressing malignancies.
- Top Cited PapersOpen Access
- 30 September 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-19
CRISPR/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells
Chimeric antigen receptor (CAR)-modified natural killer (NK) cells show antileukemic activity against acute myeloid leukemia (AML) in vivo. However, NK cell-mediated tumor killing is often impaired by the interaction between human leukocyte antigen (HLA)-E and the inhibitory receptor, NKG2A. Here, we describe a strategy that overcomes CAR-NK cell inhibition mediated by the HLA-E-NKG2A immune checkpoint. We generate CD33-specific, AML-targeted CAR-NK cells (CAR33) combined with CRISPR/Cas9-based gene disruption of the NKG2A-encoding KLRC1 gene. Using single-cell multi-omics analyses, we identified transcriptional features of activation and maturation in CAR33-KLRC1ko-NK cells, which are preserved following exposure to AML cells. Moreover, CAR33-KLRC1ko-NK cells demonstrate potent antileukemic killing activity against AML cell lines and primary blasts in vitro and in vivo. We thus conclude that NKG2A-deficient CAR-NK cells have the potential to bypass immune suppression in AML.
- 30 September 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-19
Top Cited PapersOpen AccessCRISPR/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells
Chimeric antigen receptor (CAR)-modified natural killer (NK) cells show antileukemic activity against acute myeloid leukemia (AML) in vivo. However, NK cell-mediated tumor killing is often impaired by the interaction between human leukocyte antigen (HLA)-E and the inhibitory receptor, NKG2A. Here, we describe a strategy that overcomes CAR-NK cell inhibition mediated by the HLA-E-NKG2A immune checkpoint. We generate CD33-specific, AML-targeted CAR-NK cells (CAR33) combined with CRISPR/Cas9-based gene disruption of the NKG2A-encoding KLRC1 gene. Using single-cell multi-omics analyses, we identified transcriptional features of activation and maturation in CAR33-KLRC1ko-NK cells, which are preserved following exposure to AML cells. Moreover, CAR33-KLRC1ko-NK cells demonstrate potent antileukemic killing activity against AML cell lines and primary blasts in vitro and in vivo. We thus conclude that NKG2A-deficient CAR-NK cells have the potential to bypass immune suppression in AML.